All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Aligos Therapeutics, the most common co-covered peer. The tracked stories average 2 original sources each. Atlanticus Holdings Corporation appears in 1 tracked Biotech story from August 9, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Atlanticus Holdings Corporation
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Aligos Therapeutics, the most common co-covered peer. The tracked stories average 2 original sources each. Atlanticus Holdings Corporation appears in 1 tracked Biotech story from August 9, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Atlanticus Holdings Corporation. Shared-story counts are live from our verified record — not editorial picks.
Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Atlanticus Holdings Corporation is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
